“…Matching B cell heavy chain V and J genes and assessing sequence similarity in the heavy chain CDR3 (CDRH3) region are criteria typically used to identify similar B cell clonotypes in different subject cohorts [ 19 , 21 , 22 , 32 , [34] , [35] , [36] , [37] , [38] ]. Clonotypes from both naïve BNT162b2 vaccinees [ 21 , 22 , 32 ] and convalescent unvaccinated individuals [ 19 , [34] , [35] , [36] , [37] , [38] ] have been found to be homologous with published antibodies and/or amongst different individuals based on the above criteria, showing convergent development of conserved variable region genes and sequences that work to target SARS-CoV-2. Many of these clonotypes have been identified to specifically target RBD, with subsets of these antibody clones shown to be neutralizing [ 32 , 34 , 36 ].…”